Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Methyl-CpG-binding domain protein 2 (Mbd2) as a therapeutic target in breast cancer.
FY 2023-24
Summary
DNA methylation machineries are dysregulated in cancer and are prime targets for pharmacological manipulation. We have previously shown that methyl-CpG-binding protein 2 (Mbd2) plays a causal role in cancer progression, as it is involved in tumorigenesis and metastasis. However, in vivo evidence is lacking. We hypothesize that Mbd2 plays a causal role in tumor progression and thus, targeting Mbd2 and its functional “synthetic lethal partners” can serve as a novel therapeutic approach to breast cancer. In these studies, we will assess both the therapeutic potential of Mbd2 blockage on breast cancer growth and metastasis, and the therapeutic potential of combining Mbd2 depletion with its downstream or upstream mediators and “synthetic lethal partners to block breast cancer metastasis. These studies will use our well-characterized in vitro and in vivo approaches and models. Pharmacological and molecular inhibition of Mbd2 will be carried out using CRISPR gRNA and a small molecule inhibitor of Mbd2, KCC-07. The effect of Mbd2 inhibition on human and mouse triple negative breast cancer cells' proliferation, invasion, and apoptosis will be examined in vitro. We will use our in vivo models, to which tumor cells have been inoculated via mammary fat pad and intra tibial routes, to evaluate the effect on tumor growth and metastasis to non skeletal and skeletal sites.
These studies will define the effect of blocking Mbd2 on breast cancer growth, providing evidence for Mbd2 as a therapeutic target in breast cancer. This research will lead to future clinical trials and to the development of clinical-grade Mbd2 inhibitors for evaluation in patients, which, if successful, could reduce breast cancer-associated morbidity and mortality.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
506009
Name
Dumas Olivia R
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Methyl-CpG-binding domain protein 2 (Mbd2) as a therapeutic target in breast cancer.
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Cancer; Dna Methylation; Epigenetics; Malignancy; Metastasis; Population Health; Therapeutic Target; Tumorigenesis
Abstract
DNA methylation machineries are dysregulated in cancer and are prime targets for pharmacological manipulation. We have previously shown that methyl-CpG-binding protein 2 (Mbd2) plays a causal role in cancer progression, as it is involved in tumorigenesis and metastasis. However, in vivo evidence is lacking. We hypothesize that Mbd2 plays a causal role in tumor progression and thus, targeting Mbd2 and its functional “synthetic lethal partners” can serve as a novel therapeutic approach to breast cancer. In these studies, we will assess both the therapeutic potential of Mbd2 blockage on breast cancer growth and metastasis, and the therapeutic potential of combining Mbd2 depletion with its downstream or upstream mediators and “synthetic lethal partners to block breast cancer metastasis. These studies will use our well-characterized in vitro and in vivo approaches and models. Pharmacological and molecular inhibition of Mbd2 will be carried out using CRISPR gRNA and a small molecule inhibitor of Mbd2, KCC-07. The effect of Mbd2 inhibition on human and mouse triple negative breast cancer cells' proliferation, invasion, and apoptosis will be examined in vitro. We will use our in vivo models, to which tumor cells have been inoculated via mammary fat pad and intra tibial routes, to evaluate the effect on tumor growth and metastasis to non skeletal and skeletal sites.
These studies will define the effect of blocking Mbd2 on breast cancer growth, providing evidence for Mbd2 as a therapeutic target in breast cancer. This research will lead to future clinical trials and to the development of clinical-grade Mbd2 inhibitors for evaluation in patients, which, if successful, could reduce breast cancer-associated morbidity and mortality.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Dumas, Olivia R
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~